PubRank

Erwin G Van Meir

Author PubWeight™ 125.85‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The somatic genomic landscape of glioblastoma. Cell 2013 11.73
2 Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 2015 5.71
3 Natural mutagenesis of human genomes by endogenous retrotransposons. Cell 2010 5.50
4 An integrative approach for in silico glioma research. IEEE Trans Biomed Eng 2010 4.55
5 Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012 4.13
6 The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 2005 3.42
7 BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008 2.81
8 Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004 2.79
9 Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005 2.74
10 Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 2004 2.71
11 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006 2.37
12 Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004 2.03
13 Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 2005 1.67
14 Integrative, multimodal analysis of glioblastoma using TCGA molecular data, pathology images, and clinical outcomes. IEEE Trans Biomed Eng 2011 1.63
15 Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002 1.62
16 Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 2005 1.61
17 Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 2004 1.61
18 Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol 2004 1.58
19 Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene 2002 1.58
20 Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 2014 1.56
21 Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005 1.52
22 Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002 1.52
23 PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion. J Biol Chem 2004 1.47
24 Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013 1.43
25 Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res 2009 1.39
26 Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res 2003 1.36
27 TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 2013 1.35
28 Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res 2009 1.33
29 Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004 1.32
30 Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol 2002 1.29
31 PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005 1.28
32 MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One 2013 1.25
33 The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol 2012 1.25
34 Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med 2009 1.23
35 Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 2006 1.23
36 Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 2009 1.22
37 Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol 2003 1.21
38 Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res 2007 1.20
39 Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res 2004 1.19
40 Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res 2004 1.16
41 Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res 2006 1.13
42 A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003 1.12
43 Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization. BMC Evol Biol 2005 1.11
44 TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 2003 1.06
45 Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 2007 1.06
46 Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci 2003 1.04
47 Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development. J Mol Med (Berl) 2011 1.04
48 Inhibitors of hypoxia-inducible factor-1 signaling. Curr Opin Investig Drugs 2006 1.04
49 Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 2004 1.02
50 Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review). Int J Oncol 2003 1.01
51 Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med (Berl) 2009 1.01
52 Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorg Med Chem Lett 2011 1.01
53 Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment. Mol Ther 2008 1.00
54 Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent. Bioorg Med Chem 2012 0.99
55 Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. Oncogene 2003 0.99
56 Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. J Med Chem 2011 0.99
57 Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 2014 0.99
58 Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003 0.98
59 Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res 2012 0.97
60 Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1. Cancer Res 2011 0.97
61 Stat3 activation is required for the growth of U87 cell-derived tumours in mice. Eur J Cancer 2008 0.97
62 Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro Oncol 2011 0.97
63 Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol 2010 0.97
64 Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment. Cancer J 2012 0.94
65 Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy. Clin Cancer Res 2006 0.93
66 Attractin is elevated in the cerebrospinal fluid of patients with malignant astrocytoma and mediates glioma cell migration. Clin Cancer Res 2006 0.92
67 BAI1 regulates spatial learning and synaptic plasticity in the hippocampus. J Clin Invest 2015 0.92
68 Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density. J Biol Chem 2013 0.91
69 P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3. J Clin Invest 2012 0.90
70 Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 2006 0.89
71 Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents. J Med Chem 2012 0.89
72 Cancer scene investigation: how a cold virus became a tumor killer. Future Oncol 2005 0.88
73 KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One 2012 0.86
74 Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Cancer Res 2002 0.86
75 At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop. J Mol Med (Berl) 2011 0.85
76 Absence of KLF6 gene mutations in human astrocytic tumors and cell lines. Int J Cancer 2004 0.81
77 P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway. Cancer Res 2014 0.81
78 Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma. Cancer Res 2002 0.80
79 A conspiracy of glioma and endothelial cells to invade the normal brain. Oncotarget 2011 0.79
80 WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun 2014 0.79
81 Overcoming therapeutic resistance in glioblastoma: the way forward. J Clin Invest 2017 0.75
82 Opening the chamber of peer-review secrets. Nature 2004 0.75